Lipids & metabolic liver disease
Hepatic steatosis with significant fibrosis is associated with preclinical carotid atherosclerosis in patients with type 1 diabetes
Authors' conclusion
Hepatic fibrosis markers are associated with increased carotid atherosclerosis in T1D. Non-invasive MASLD scores could help identify T1D patients at higher CVD risk.
Study context
- Population
- T1D individuals without cardiovascular disease (CVD) with ≥1 of: ≥40 years, diabetic kidney disease, and/or ≥10 years of T1D duration with CVD risk factors; 49.8 % women, age 47.8 ± 10.7 years, T1D duration 26.9 ± 10.8 years, BMI 26.1 ± 4.3 kg/m²
- Participants
- 679 individuals
- Exposure
- No steatosis vs steatosis vs steatosis + fibrosis
- Outcome
- Preclinical atherosclerosis (carotid plaques) by carotid US
Main finding
As reported in the abstract
Carotid plaques, HSI + FIB-4
Steatosis + fibrosis vs No steatosisOdds ratio (CI)
Plaque presence; adjusted for conventional and T1D-specific risk factors
1.97(1.02–3.82)
≥ 2 plaques; adjusted for conventional and T1D-specific risk factors
1.97(1.01–3.84)
Observational data: associations, not effects.
Further findings
Carotid plaques, FLI + FIB-4 — between No steatosis and Steatosis + fibrosis · across the three groups
P < 0.01
Prevalence of steatosis and steatosis + fibrosis
%
- Steatosis by Hepatic Steatosis Index (HSI)
- 45.2
- Steatosis + fibrosis by HSI
- 8.4
- Steatosis by Fatty Liver Index (FLI)
- 13.7
- Steatosis + fibrosis by FLI
- 5.1
Original publication
Hepatic steatosis with significant fibrosis is associated with preclinical carotid atherosclerosis in patients with type 1 diabetes. Diabetes Res Clin Pract. Published 19 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →